Overall survival† · people with cutaneous melanoma
MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.85 [0.58, 1.25]
496 participants
Low
Progression‐free survival · people with cutaneous melanoma
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.58 [0.42, 0.8]
496 participants
Moderate
Tumour response · people with cutaneous melanoma
MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 2.01 [1.35, 2.99]
496 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.61 [1.08, 2.41]
91 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 3.42 [2.38, 4.92]
1367 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
1 finding from 1 review
0.55 [0.31, 0.97]
1360 participants
Low
Clinical cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes clinical cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes mycological cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event Pain as · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Time needed until improvement ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Physician‐assessed changes in clinical signs · atopic eczema
1 finding from 1 review